| Document |
Document Title |
|
WO/2023/212091A1 |
Novel ester compounds are provided herein that when administered to a mammal (e.g., to a human) are hydrolyzed to produce 1) ketone bodies or immediate precursors to ketone bodies; 2) lactate or immediate precursors to lactate; and/or 3)...
|
|
WO/2023/208755A1 |
The present invention relates to a method of producing calcium oxalate from calcium carbonate the method comprising the steps of: (a) producing CO2 by contacting calcium carbonate with at least one acid; (b) isolating the CO2 produced fr...
|
|
WO/2023/197901A1 |
The present invention relates to the technical field of biopharmaceuticals, and in particular to a tumor cell-derived microparticle loaded with succinic acid, a preparation method therefor, and use thereof. Provided is a tumor cell-deriv...
|
|
WO/2023/196900A1 |
Provided herein are solid forms comprising a compound of formula (I), or a stereoisomer, or a mixture of stereoisomers thereof, or a pharmaceutically acceptable salt thereof. Also provided herein are methods of synthesizing a compound of...
|
|
WO/2023/187421A1 |
The application relates to the besylate, phosphate, tartrate, fumarate and succinate salts of mesembrine, also known as 3a-(3,4- dimethoxyphenyl)-octahydro-1-methyl-6H-indol-6-one. Mesembrine has the chemical formula C17H23NO3. The appli...
|
|
WO/2023/179771A1 |
Provided herein are salts and crystalline forms of Compound (I), and salts, solvates, and salt solvates thereof. Also provided herein are pharmaceutical compositions comprising the crystalline forms, and therapeutic uses of the crystalli...
|
|
WO/2023/180898A1 |
This invention relates to a crystalline anhydrous form of (S)-1'-(6-((2-amino-3-chloropyridin-4-yl)thio)-1,2,4-triazin
-3-yl)-1,3-dihydrospiro[indene-2,4'-piperidin]-1-amine mono succinate salt Form 1. The invention also relates to pharm...
|
|
WO/2023/157982A1 |
The purpose of the present disclosure is to provide a method for isolating a fluorocarbon having one carbon atom. A fluorocarbon isolation method according to the present disclosure comprises isolating a fluorocarbon having n carbon at...
|
|
WO/2023/150169A1 |
The present invention provides ionizable polyesters, compositions comprising ionizable polyester polyplexes, and methods of delivering nucleic acids to cells comprising administering the polyplexes to subjects.
|
|
WO/2023/147779A1 |
Provided are a preparation method of a pyridazinone derivative, an intermediate thereof, and a preparation method of the intermediate. The method has the advantages of easily available raw materials, simple steps, low costs, good interme...
|
|
WO/2023/150706A1 |
Provided herein are solid forms of 1-((S)-4-((R)-7-(6-amino-4-methyl-3- (trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-m
ethylpyrrolidin-2- yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en
-1-one and methods of th...
|
|
WO/2023/149514A1 |
The present invention relates to a method for producing a dicarboxylic acid compound and/or a diamine compound and optionally a dehydration-condensation product of a dicarboxylic acid compound and a diamine compound (i.e., a dehydration-...
|
|
WO/2023/131667A1 |
Embodiments of the invention are directed to cooling compounds and cooling compositions having a unique cooling perception, as well as various edible, potable, and/or cosmetic products containing one or more cooling compounds having a ge...
|
|
WO/2023/110784A1 |
The present invention relates to a compound of Formula I, Li(ox)]2[M1mM2nM3k(OH)pFq; wherein M1, M2 and M3 are metals; and X is a halogen chosen from F, Cl and Br; and m, n and k are, independently, a number between 0 and 5, the sum of m...
|
|
WO/2023/083983A1 |
The present invention thus provides a novel family of liposomal compositions (nanocarriers), hereinafter referred to as Tetra-Acidosomes, comprising natural tetrameric acid (TA) lipids and/or novel chemically functionalized tetrameric ac...
|
|
WO/2023/071938A1 |
The present invention relates to a method for producing succinic anhydride by means of maleic anhydride hydrogenation, comprising (1) a maleic anhydride solution and a hydrogen raw material respectively enter a first-stage hydrogenation ...
|
|
WO/2023/073606A1 |
The present invention relates to an industrially feasible and economically viable process for preparation of Edoxaban key intermediate viz. compound of formula (1) which is shown below:
|
|
WO/2023/066820A1 |
The invention relates to a co-crystal of citric acid and glycine, said co-crystal containing citric acid and glycine in a molar ratio of 1:3. The inventors have unexpectedly discovered that this co-crystal of citric acid and glycine can ...
|
|
WO/2023/061437A1 |
The present invention relates to a salt of an antitumor drug and a crystal form thereof, and specifically relates to a pharmaceutical salt of the compound N-(3-(2-((2-methoxy-4-(4-methyl-1-piperazinyl)phenyl)amino)-
7-oxo-6-phenyl-8(7H)-...
|
|
WO/2023/064888A1 |
Small, low molecular weight compounds which inhibit the cellular activity of P-type Cu-ATPases, ATP7A and/or ATP7B, and pharmaceutical compositions containing the compounds, are described. Methods of using said compounds in the treatment...
|
|
WO/2023/064363A1 |
The present disclosure relates to novel salts and salt forms of (2R)-2-(2-chlorophenyl)-2- (methylamino)cyclohexan-1-one (R-ketamine) and to processes for their preparation. The disclosure is also directed to pharmaceutical compositions ...
|
|
WO/2023/052192A1 |
The present disclosure relates to a method of sequestering carbon dioxide which comprises the steps of capturing carbon dioxide from an industrial gaseous waste stream and/or the atmosphere, converting a CO2 from the CO2 gas stream into ...
|
|
WO/2023/045985A1 |
Disclosed are a long-chain compound and the use thereof. The structure of the long-chain compound is as shown in formula (I). The compound can directly inhibit ACLY, has a significant therapeutic effect on metabolic diseases represented ...
|
|
WO/2023/045986A1 |
A long-chain compound, a preparation method therefor and the use thereof are disclosed. The structure of said compound is represented by formula (I). The definition of each substituent in the formula is as set out in the description and ...
|
|
WO/2023/044326A1 |
The present invention relates to specific salts of (1S,5R)-(1α,5α,6α)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl
)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of usin...
|
|
WO/2023/040406A1 |
A preparation method for a ferrous oxalate lithium ion battery negative electrode with an ordered three-dimensional skeleton structure. The method comprises: preparing a metal source solution and an oxalic acid or an acidic oxalate solut...
|
|
WO/2023/015706A1 |
The present invention relates to a catalytic reaction, in particular, to a catalytic oxidation device and method. The catalytic oxidation device comprises a storage unit, a premixing unit, a microchannel reaction unit, a gas-liquid separ...
|
|
WO/2023/015709A1 |
Provided is a catalyst. Specifically, the present invention relates to a carbon-based metal-free functional quantum dot, a preparation method therefor and an application thereof. The preparation method comprises the following steps: S1: ...
|
|
WO/2023/015343A1 |
A plasma-bubble reactor, reactor system and method for producing hydrogen peroxide (H2O2), one or more hydrocarbon(s), and syngas is disclosed. The reactor comprises a vessel configured to hold a liquid; and a plasma generating means, in...
|
|
WO/2022/271846A1 |
Various salt and polymorph forms of Compound (I) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. Particular crystalline forms of 1:0.5 Compound (I) Semi-Succinate, 1:0....
|
|
WO/2022/269041A1 |
The present invention is directed to a method for continuous production of cationic lipids. Said cationic lipids are particularly useful in combination with other lipid components for forming lipid nanoparticles with oligonucleotides (e....
|
|
WO/2022/268849A1 |
A novel crystalline formof 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N
- methylazetidin-3-amine hemisuccinate is provided along with pharmaceutical compositions comprising the same. Also disclosed is the use of the novel...
|
|
WO/2022/261401A1 |
Solid state forms of Abexinostat salts and of Abexinostat tosylate : p-toluenesulfonic acid monohydrate complex, processes for preparation thereof, pharmaceutical compositions and uses thereof are disclosed.
|
|
WO/2022/258732A1 |
The present invention concerns a process for the recovery and purification of glyoxylic acid from a process stream comprising glyoxylic acid and oxalic acid, wherein the process stream comprising glyoxylic acid and oxalic acid is subject...
|
|
WO/2022/253907A1 |
The invention provides a pharmaceutically acceptable salt of 5-[[5-[4-(4-fluoro-1-methyl-4-piperidyl)-2-methoxy-phenyl]-1
H-pyrazol-3-yl]amino]pyrazine-2-carbonitrile which is selected from maleate, tosylate, besylate and malonate salts....
|
|
WO/2022/247214A1 |
The present invention relates to the technical fields of nanomaterials and catalysis, and in particular, to a glutaric acid selective polyacid catalyst based on a micro-mesoporous Zr-MOF material, a preparation method therefor and an app...
|
|
WO/2022/251169A1 |
Crystalline salts of psilocin are disclosed. The beneficial and therapeutic uses of the crystalline psilocin salts and of compositions containing the crystalline psilocin salts are also disclosed. The disclosure sets out methods of makin...
|
|
WO/2022/238389A2 |
The present disclosure relates to various crystalline forms of entinostat and to processes for their preparation, particularly Form A of entinostat compound with maleic acid, Form A of entinostat compound with succinic acid, Form B of en...
|
|
WO/2022/240920A1 |
Provided herein are cocrystalline forms including BTK-I useful in the treatment and prevention of diseases which can be treated with a BTK inhibitor, including BTK-associated diseases and disorders, characterizations, and methods of maki...
|
|
WO/2022/236127A1 |
Provided is a first process of producing an anhydride of an organic mono-acid comprising performing a transanhydridization reaction of an organic mono-acid and a thermally regenerable anhydride to produce the anhydride of the organic mon...
|
|
WO/2022/227668A1 |
A recovery method for lithium iron phosphate waste and an application. The method comprises the following steps: mixing lithium iron phosphate waste with water to make a slurry, adding alkali to adjust a pH until the slurry is alkaline, ...
|
|
WO/2022/204752A1 |
Disclosed herein is a method for producing iron (II) oxalate from an insoluble iron material, the method comprising digesting the insoluble iron material with a digestion liquor comprising one or more acids, and reacting digested iron sp...
|
|
WO/2022/194863A1 |
Process for obtaining dicarboxylic acids from a mixture of triglycerides of dicarboxylic acids comprising the steps of a) hydrolysing said mixture of triglycerides of dicarboxylic acids in the presence of a basic aqueous solution, result...
|
|
WO/2022/191314A1 |
The present invention makes it possible to produce adipic acid at a high selectivity without emitting dinitrogen monoxide by using a 3-hydroxyadipic acid 3,6-lactone composition as a starting material, the composition containing 3 to 30 ...
|
|
WO/2022/187235A1 |
In various embodiments, the present invention relates to a series 3D printable, biodegradable, poly(propylene fumarate) derivative ABA type triblock copolymers having a flexible propylene succinate core unit synthesized through ring-open...
|
|
WO/2022/174628A1 |
The invention relates to a method for co-producing adipic acid and cyclohexanone oxime from cyclohexane. The method comprises: (1) subjecting cyclohexane and NO x to oxidation nitration to generate adipic acid, nitrocyclohexane, a nitrog...
|
|
WO/2022/148797A1 |
Process for preparing potassium oxalate which process comprises contacting potassium formate with a base catalyst at a temperature of from 140 to 260°C which base catalyst is a metal hydride.
|
|
WO/2022/132694A1 |
A system for glucaric acid production, the system comprising: (a) a first input selected from the group consisting of glucuronolactone, a disaccharide feedstock, a cleaved starch, a disaccharide, glucuronic acid, or a combination thereof...
|
|
WO/2022/106549A1 |
The present invention relates to salt forms of the following compound (I).
|
|
WO/2022/107695A1 |
A method for producing barium titanyl oxalate, wherein barium titanyl oxalate is produced by mixing and reacting a solution containing oxalic acid (solution A) and a solution containing a titanium source and a barium source (solution B) ...
|
